Report
Share
Download to read offline
Recommended
Most commercial insulin assays fail to detect recombinant insulin analogues
Most commercial insulin assays are unable to accurately detect recombinant insulin analogues. A study published in 2006 found that many insulin tests on the market fail to measure modern insulin formulations that are genetically engineered versions of human insulin. This can lead to incorrect results when monitoring insulin levels in patients taking analogues.
IDF Presentation to 2011 Roche Social Media Summit
The International Diabetes Federation (IDF) is a global organization focused on diabetes care, prevention, and treatment. It has over 220 member associations in over 160 countries. The IDF aims to stem the growing global diabetes epidemic by advocating for policies and programs, raising awareness through events like World Diabetes Day, publishing research on diabetes prevalence and costs, and convening the global diabetes community. In the lead up to the 2011 UN Summit on non-communicable diseases, the IDF is lobbying governments to commit to national diabetes plans and increased resources to fight diabetes worldwide.
Roche Social Media Summit June 2011
The document outlines the agenda for Roche's 2011 Social Media Summit, including presentations and discussions on emerging diabetes social media trends, Roche products like insulin pumps and meters, and workshops on developing ideas for engaging the diabetes community online. The summit brings together Roche representatives and guests from diabetes organizations to share insights and strategize ways to enhance digital outreach efforts.
The Glucose Getaway
This document discusses how new diabetes technologies promise easier management but many people still struggle to maintain control or avoid burnout. While technology helps, people need breaks from the constant demands of diabetes care. The document contrasts unsafe breaks like ignoring treatment with safe breaks like occasional relaxed monitoring that don't compromise long-term health but provide needed relief. It encourages planning occasional breaks to sustain motivation and enjoying life with diabetes.
Insulin analogues ppt
This document discusses insulin analogues, which are genetically engineered versions of human insulin that have altered pharmacokinetic properties. It describes the classification of insulin analogues as either short-acting like lispro, aspart, and glulisine, or long-acting like glargine, detemir, and degludec. Insulin analogues were developed to overcome limitations of standard insulins like regular and NPH insulins in order to better mimic the body's natural insulin secretion and reduce risks of hypoglycemia. While analogues provide benefits like improved glucose control and flexibility, their higher cost is a drawback.
Spinach and Artichoke Dip (Associated Press)
This recipe provides instructions for making a spinach and artichoke dip appetizer. It calls for Greek yogurt, cream cheese, spinach, artichoke hearts, onions, herbs, and crushed whole-grain crackers. The ingredients are combined and baked for 10-15 minutes until hot. The dip serves 8 people and each serving contains 32 calories, 2g fat, 1g protein, and 3g carbohydrates.
Larry Soler Transcript-2004
The document contains a transcript of an online discussion between Larry Soler, Vice President of Government Relations at the Juvenile Diabetes Research Foundation (JDRF), and several participants. Soler discusses JDRF's advocacy efforts and priorities, which include expanding stem cell research policies, increasing funding for juvenile diabetes research, and increasing the availability of pancreases for islet cell transplants. He explains how JDRF utilizes volunteers and grassroots organizing to effectively lobby Congress and influence policy on issues related to diabetes research.
Letter to Express Scripts Cash-Pay Mail Order Pharmacy by InsideRx
Letter from InsideRx regarding Express Scripts Cash-Pay Mail Order Pharmacy by InsideRx Going Forward
Recommended
Most commercial insulin assays fail to detect recombinant insulin analogues
Most commercial insulin assays are unable to accurately detect recombinant insulin analogues. A study published in 2006 found that many insulin tests on the market fail to measure modern insulin formulations that are genetically engineered versions of human insulin. This can lead to incorrect results when monitoring insulin levels in patients taking analogues.
IDF Presentation to 2011 Roche Social Media Summit
The International Diabetes Federation (IDF) is a global organization focused on diabetes care, prevention, and treatment. It has over 220 member associations in over 160 countries. The IDF aims to stem the growing global diabetes epidemic by advocating for policies and programs, raising awareness through events like World Diabetes Day, publishing research on diabetes prevalence and costs, and convening the global diabetes community. In the lead up to the 2011 UN Summit on non-communicable diseases, the IDF is lobbying governments to commit to national diabetes plans and increased resources to fight diabetes worldwide.
Roche Social Media Summit June 2011
The document outlines the agenda for Roche's 2011 Social Media Summit, including presentations and discussions on emerging diabetes social media trends, Roche products like insulin pumps and meters, and workshops on developing ideas for engaging the diabetes community online. The summit brings together Roche representatives and guests from diabetes organizations to share insights and strategize ways to enhance digital outreach efforts.
The Glucose Getaway
This document discusses how new diabetes technologies promise easier management but many people still struggle to maintain control or avoid burnout. While technology helps, people need breaks from the constant demands of diabetes care. The document contrasts unsafe breaks like ignoring treatment with safe breaks like occasional relaxed monitoring that don't compromise long-term health but provide needed relief. It encourages planning occasional breaks to sustain motivation and enjoying life with diabetes.
Insulin analogues ppt
This document discusses insulin analogues, which are genetically engineered versions of human insulin that have altered pharmacokinetic properties. It describes the classification of insulin analogues as either short-acting like lispro, aspart, and glulisine, or long-acting like glargine, detemir, and degludec. Insulin analogues were developed to overcome limitations of standard insulins like regular and NPH insulins in order to better mimic the body's natural insulin secretion and reduce risks of hypoglycemia. While analogues provide benefits like improved glucose control and flexibility, their higher cost is a drawback.
Spinach and Artichoke Dip (Associated Press)
This recipe provides instructions for making a spinach and artichoke dip appetizer. It calls for Greek yogurt, cream cheese, spinach, artichoke hearts, onions, herbs, and crushed whole-grain crackers. The ingredients are combined and baked for 10-15 minutes until hot. The dip serves 8 people and each serving contains 32 calories, 2g fat, 1g protein, and 3g carbohydrates.
Larry Soler Transcript-2004
The document contains a transcript of an online discussion between Larry Soler, Vice President of Government Relations at the Juvenile Diabetes Research Foundation (JDRF), and several participants. Soler discusses JDRF's advocacy efforts and priorities, which include expanding stem cell research policies, increasing funding for juvenile diabetes research, and increasing the availability of pancreases for islet cell transplants. He explains how JDRF utilizes volunteers and grassroots organizing to effectively lobby Congress and influence policy on issues related to diabetes research.
Letter to Express Scripts Cash-Pay Mail Order Pharmacy by InsideRx
Letter from InsideRx regarding Express Scripts Cash-Pay Mail Order Pharmacy by InsideRx Going Forward
Amphastar Pharmaceuticals Sep 2022 Corp Presentation-Insulin Biosims.pdf
Amphastar Pharmaceuticals Outlines its Key Drug Development Pipeline as of September 2022, including several insulin biosimilars.
JDRF-Civica Rx Insulin-Announcement
Civica will manufacture and distribute biosimilar insulins at an affordable price to help the millions of Americans who struggle to afford life-saving insulin medications. They plan to produce glargine, lispro and aspart insulin and sell them for no more than $30 per vial or $55 for a box of pen cartridges. This would represent up to a 90% discount compared to current market prices and ensure no one has to ration insulin due to cost. JDRF and other organizations are partnering with Civica to help reduce healthcare disparities and make insulin universally accessible.
JDRF-Civica Insulin Announcement Fact Sheet
On March 3, 2022, the nonprofit drug company Civica Rx announced its intention to introduce 3 insulin biosimilars at list prices which promise to be below copays and cost-sharing on insulin for many insured patients, as well as much less costly for uninsured patients.
Right Care Alliance Presentation
This document provides background information on Scott Strumello and his assessment of why insulin prices are so high in the US. It discusses how Strumello investigated the issue and found that while drug companies share some blame, the primary culprits are health insurance companies. Insurance companies collect large rebates on insulin but fail to pass these savings to patients, instead using the money to offer premium discounts to employers. This forces many patients to pay the full list price of insulin out of pocket due to high deductible plans. While drug companies, pharmacy benefit managers, and legislators all play a role, Strumello argues that insurance companies deserve most of the blame for the rising out-of-pocket costs that patients face.
1992 Heritage Consumer Choice Health Plan
This was the Heritage Foundation's proposal for a healthcare plan which would later become the basis for the Affordable Care Act
Biodel, Inc. Investor Presentation January 14, 2010
This document summarizes a presentation given at the 28th Annual Healthcare Conference in San Francisco on January 14, 2010. The presentation was given by Biodel Inc., a company focused on developing enhanced insulin therapies for diabetes. Biodel discussed their lead product candidate VIAject, an ultra rapid-acting prandial insulin, which completed two successful Phase 3 trials and is awaiting FDA approval. The presentation provided an overview of Biodel's pipeline of diabetes programs, the insulin market opportunity, and preclinical and clinical data demonstrating VIAject's superior pharmacokinetic and pharmacodynamic profile compared to existing rapid-acting insulins.
Pet contest winners
Lola, a 2-year-old Yorkshire terrier, won first place in the "Smartest Pet in Queens" contest. She knows tricks like sit, paw down, and up, and likes to pretend fly. Princess, a mixed breed dog, came in second place. She can hold a ball in her mouth with her paws and prays without a ball. Phyllis, a half Siamese cat, took third place. She alerts her owner Scott of his juvenile diabetes episodes and ensures he is okay at night.
JDRF Countdown July 2009
One of the latest success stories in diabetes research has been the development of anti-CD3 monoclonal antibodies to slow the progression of type 1 diabetes, which has been in development for over a decade. Two biotechnology companies, MacroGenics and Tolerx, are currently conducting phase III clinical trials testing different anti-CD3 drugs, with the goal of preserving insulin-producing beta cell function and reducing insulin needs. If successful, the results of these trials could provide evidence for FDA approval of anti-CD3 therapy as a treatment for newly diagnosed type 1 diabetes patients.
Bentley (College) University Society Monthly Review
Inaugural issue of "Society Monthly Review" magazine published by the Bentley Student Union Society in April 1991.
Treatment of patients with new onset Type 1 diabetes with a single course of ...
Authors: Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Inger Mollerup, Vice President of Novo Nordisk A/S, testified before the Government Oversight and Reform Committee about establishing a pathway for approval of follow-on biologics. She argued that any pathway must require clinical trials to demonstrate safety because even minor differences in biologics can have major health consequences, as shown through Novo Nordisk's experience. She also stated that traceability and unique names are important for pharmacovigilance, and that interchangeability is not supported by current science given potential immunogenicity differences between products.
Stanford University Case Study: Novo Nordisk
Novo Nordisk was historically the second largest producer of insulin in the world in 1981, supplying 25% of global demand. While it dominated the European market, it held less than 5% share in the large and lucrative US market, which was dominated by Eli Lilly at 83% share. By 1995, the insulin industry had consolidated significantly due to changes in technology, regulation, and competition. Novo broadened its product portfolio and global presence but continued to trail Eli Lilly in the important US market. Managing this competitive challenge would be a focus for Novo Nordisk's leadership going forward.
Could Generic Insulin Soon Hit the U.S. Market?
Diabetes blogger Scott Strumello (sstrumello.blogspot.com) investigates whether follow-on (generic) insulin formulation will soon emerge in accordance with U.S. patent law.
Publish Date: January 1, 2007
Mr. Hypo Is My Friend
Created by Dianne Maurlyn Wenger
dedicated to Joanie
Illustrations by Robert Clos
For Ames Company (now Bayer Diabetes Care)
Different Potencies of Biosynthetic Human and Purified Porcine Insulin
The document summarizes research comparing the biological activity of purified porcine insulin and Biosynthetic Human Insulin (BHI) using the glucose clamp technique. The study found that:
1) BHI required significantly more glucose infusion than purified porcine insulin to maintain euglycemia, indicating BHI had higher biological activity.
2) Purified porcine insulin, but not BHI, induced significant increases in serum growth hormone and Cortisol concentrations.
3) There were no significant differences in serum insulin, glucose, or C-peptide levels between the two insulins.
More Related Content
More from sstrumello
Amphastar Pharmaceuticals Sep 2022 Corp Presentation-Insulin Biosims.pdf
Amphastar Pharmaceuticals Outlines its Key Drug Development Pipeline as of September 2022, including several insulin biosimilars.
JDRF-Civica Rx Insulin-Announcement
Civica will manufacture and distribute biosimilar insulins at an affordable price to help the millions of Americans who struggle to afford life-saving insulin medications. They plan to produce glargine, lispro and aspart insulin and sell them for no more than $30 per vial or $55 for a box of pen cartridges. This would represent up to a 90% discount compared to current market prices and ensure no one has to ration insulin due to cost. JDRF and other organizations are partnering with Civica to help reduce healthcare disparities and make insulin universally accessible.
JDRF-Civica Insulin Announcement Fact Sheet
On March 3, 2022, the nonprofit drug company Civica Rx announced its intention to introduce 3 insulin biosimilars at list prices which promise to be below copays and cost-sharing on insulin for many insured patients, as well as much less costly for uninsured patients.
Right Care Alliance Presentation
This document provides background information on Scott Strumello and his assessment of why insulin prices are so high in the US. It discusses how Strumello investigated the issue and found that while drug companies share some blame, the primary culprits are health insurance companies. Insurance companies collect large rebates on insulin but fail to pass these savings to patients, instead using the money to offer premium discounts to employers. This forces many patients to pay the full list price of insulin out of pocket due to high deductible plans. While drug companies, pharmacy benefit managers, and legislators all play a role, Strumello argues that insurance companies deserve most of the blame for the rising out-of-pocket costs that patients face.
1992 Heritage Consumer Choice Health Plan
This was the Heritage Foundation's proposal for a healthcare plan which would later become the basis for the Affordable Care Act
Biodel, Inc. Investor Presentation January 14, 2010
This document summarizes a presentation given at the 28th Annual Healthcare Conference in San Francisco on January 14, 2010. The presentation was given by Biodel Inc., a company focused on developing enhanced insulin therapies for diabetes. Biodel discussed their lead product candidate VIAject, an ultra rapid-acting prandial insulin, which completed two successful Phase 3 trials and is awaiting FDA approval. The presentation provided an overview of Biodel's pipeline of diabetes programs, the insulin market opportunity, and preclinical and clinical data demonstrating VIAject's superior pharmacokinetic and pharmacodynamic profile compared to existing rapid-acting insulins.
Pet contest winners
Lola, a 2-year-old Yorkshire terrier, won first place in the "Smartest Pet in Queens" contest. She knows tricks like sit, paw down, and up, and likes to pretend fly. Princess, a mixed breed dog, came in second place. She can hold a ball in her mouth with her paws and prays without a ball. Phyllis, a half Siamese cat, took third place. She alerts her owner Scott of his juvenile diabetes episodes and ensures he is okay at night.
JDRF Countdown July 2009
One of the latest success stories in diabetes research has been the development of anti-CD3 monoclonal antibodies to slow the progression of type 1 diabetes, which has been in development for over a decade. Two biotechnology companies, MacroGenics and Tolerx, are currently conducting phase III clinical trials testing different anti-CD3 drugs, with the goal of preserving insulin-producing beta cell function and reducing insulin needs. If successful, the results of these trials could provide evidence for FDA approval of anti-CD3 therapy as a treatment for newly diagnosed type 1 diabetes patients.
Bentley (College) University Society Monthly Review
Inaugural issue of "Society Monthly Review" magazine published by the Bentley Student Union Society in April 1991.
Treatment of patients with new onset Type 1 diabetes with a single course of ...
Authors: Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Inger Mollerup, Vice President of Novo Nordisk A/S, testified before the Government Oversight and Reform Committee about establishing a pathway for approval of follow-on biologics. She argued that any pathway must require clinical trials to demonstrate safety because even minor differences in biologics can have major health consequences, as shown through Novo Nordisk's experience. She also stated that traceability and unique names are important for pharmacovigilance, and that interchangeability is not supported by current science given potential immunogenicity differences between products.
Stanford University Case Study: Novo Nordisk
Novo Nordisk was historically the second largest producer of insulin in the world in 1981, supplying 25% of global demand. While it dominated the European market, it held less than 5% share in the large and lucrative US market, which was dominated by Eli Lilly at 83% share. By 1995, the insulin industry had consolidated significantly due to changes in technology, regulation, and competition. Novo broadened its product portfolio and global presence but continued to trail Eli Lilly in the important US market. Managing this competitive challenge would be a focus for Novo Nordisk's leadership going forward.
Could Generic Insulin Soon Hit the U.S. Market?
Diabetes blogger Scott Strumello (sstrumello.blogspot.com) investigates whether follow-on (generic) insulin formulation will soon emerge in accordance with U.S. patent law.
Publish Date: January 1, 2007
Mr. Hypo Is My Friend
Created by Dianne Maurlyn Wenger
dedicated to Joanie
Illustrations by Robert Clos
For Ames Company (now Bayer Diabetes Care)
Different Potencies of Biosynthetic Human and Purified Porcine Insulin
The document summarizes research comparing the biological activity of purified porcine insulin and Biosynthetic Human Insulin (BHI) using the glucose clamp technique. The study found that:
1) BHI required significantly more glucose infusion than purified porcine insulin to maintain euglycemia, indicating BHI had higher biological activity.
2) Purified porcine insulin, but not BHI, induced significant increases in serum growth hormone and Cortisol concentrations.
3) There were no significant differences in serum insulin, glucose, or C-peptide levels between the two insulins.
More from sstrumello (15)
Amphastar Pharmaceuticals Sep 2022 Corp Presentation-Insulin Biosims.pdf
Amphastar Pharmaceuticals Sep 2022 Corp Presentation-Insulin Biosims.pdf
Biodel, Inc. Investor Presentation January 14, 2010
Biodel, Inc. Investor Presentation January 14, 2010
Bentley (College) University Society Monthly Review
Bentley (College) University Society Monthly Review
Treatment of patients with new onset Type 1 diabetes with a single course of ...
Treatment of patients with new onset Type 1 diabetes with a single course of ...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Different Potencies of Biosynthetic Human and Purified Porcine Insulin
Different Potencies of Biosynthetic Human and Purified Porcine Insulin